Rituximab in a risk-adapted treatment strategy gives excellent therapeutic results in nodular lymphocyte-predominant Hodgkin lymphoma.
Roberta Della PepaMarco PicardiClaudia GiordanoIrene ZacheoNovella PuglieseClaudio CerchioneMarta RaimondoMaria Di PernaGiancarlo TronconeGiuseppe CianciaMariano IntrieriFabrizio PanePublished in: British journal of haematology (2017)